NCT02877212View on ClinicalTrials.gov

Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients

PHASE3UnknownINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

September 30, 2017

Conditions
Immune Thrombocytopenic Purpura (ITP)
Interventions
DRUG

Eltrombopag

Eltrombopag will be given to steroid refractory ITP patients and ITP patients treated with standard Immunosuppressive therapy (IST) will be taken as control.

Trial Locations (1)

46000

RECRUITING

Armed Forces Bone Marrow Transplant Centre, Rawalpindi

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

National Institute of Blood and Marrow Transplant (NIBMT), Pakistan

OTHER_GOV